Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr18.00 SEK
Change Today +0.40 / 2.27%
Volume 36.9K
BIOT On Other Exchanges
Symbol
Exchange
BIOT is not on other exchanges.
As of 11:29 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

biotage ab (BIOT) Snapshot

Open
kr17.50
Previous Close
kr17.60
Day High
kr18.00
Day Low
kr17.50
52 Week High
07/15/15 - kr19.30
52 Week Low
10/16/14 - kr10.45
Market Cap
1.2B
Average Volume 10 Days
60.7K
EPS TTM
kr0.96
Shares Outstanding
64.7M
EX-Date
04/29/15
P/E TM
18.8x
Dividend
kr0.75
Dividend Yield
4.17%
Current Stock Chart for BIOTAGE AB (BIOT)

Related News

No related news articles were found.

biotage ab (BIOT) Related Businessweek News

No Related Businessweek News Found

biotage ab (BIOT) Details

Biotage AB (publ) provides solutions, knowledge, and experience in the areas of analytical chemistry, medicinal chemistry, peptide synthesis, separation, and purification in the United States, Europe, and Japan. The company offers systems and related consumables for evaporation, flash purification, microwave synthesis, peptide synthesis and purification, sample preparation, work-up tools, and process development solutions in organic chemistry and analytical chemistry areas. It also offers contract-research services, as well as develops and produces polymer based materials. The company sells its products to pharmaceutical and biotech companies, contract research organizations and contract manufacturing organizations, and academic institutions. Biotage AB (publ) is headquartered in Uppsala, Sweden.

284 Employees
Last Reported Date: 08/13/15

biotage ab (BIOT) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr4.0M
Compensation as of Fiscal Year 2014.

biotage ab (BIOT) Key Developments

Biotage AB Reports Unaudited Group and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Biotage AB reported unaudited group and parent earnings results for the second quarter and six months ended June 30, 2015. Group net sales in the quarter were SEK 148.115 million, compared to SEK 120.383 million a year ago. Operating profit amounted to SEK 17.704 million against SEK 13.549 million reported last year. Profit before income tax was SEK 17.358 million against SEK 15.933 million reported last year. Net profit attributable to parent company's shareholders was SEK 13.994 million or SEK 0.22 per diluted share against SEK 18.927 million or SEK 0.29 per diluted share reported last year. Cash flow from operating activities amounted to SEK 29.039 million against SEK 24.607 million reported last year. Acquisition of property, plant and equipment was SEK 0.927 million against SEK 1.545 million reported last year. Acquisition of intangible assets was SEK 6.441 million against SEK 6.258 million reported last year. For the six months, group net sales were SEK 292.290 million, compared to SEK 234.100 million reported in the same period last year. Operating profit amounted to SEK 35.657 million against SEK 23.013 million reported last year. Profit before income tax was SEK 37.255 million against SEK 25.848 million reported last year. Net profit attributable to parent company's shareholders was SEK 41.982 million or SEK 0.65 per diluted share against SEK 26.873 million or SEK 0.42 per diluted share reported last year. Cash flow from operating activities amounted to SEK 52.847 million against SEK 35.425 million reported last year. Acquisition of property, plant and equipment was SEK 1.900 million against SEK 4.777 million reported last year. Acquisition of intangible assets was SEK 10.840 million against SEK 12.961 million reported last year. For the quarter, the parent company reported net sales of SEK 0.675 million against SEK 0.619 million reported in the same period last year. Operating loss amounted to SEK 4.802 million against operating loss SEK 4.223 million reported last year. Loss before income tax was SEK 6.042 million against SEK 2.464 million reported last year. Total loss for the period was SEK 6.042 million against SEK 2.464 million reported last year. For the six months, the parent company reported net sales of SEK 1.361 million against SEK 1.225 million reported in the same period last year. Operating loss amounted to SEK 8.681 million against operating loss SEK 9.012 million reported last year. Loss before income tax was SEK 9.587 million against SEK 6.630 million reported last year. Total loss for the period was SEK 9.587 million against SEK 6.630 million reported last year.

Scientific Plastic Products, Inc. Files Lawsuit Against Biotage for Patent Infringement

A lawsuit was filed against Biotage by Scientific Plastic Products Inc. concerning alleged infringement of the US patents no 7,138,061, 7,381,327 and 7,410,571. Biotage then filed requests with the US Patent and Trademark Office for reexamination of all patent claims in the Patents. At the same time Biotage moved to stay the lawsuit in the district court pending the outcome of the re-examination proceedings with the consent of SPP, and the court stayed the district court lawsuit pending resolution of the reexamination proceedings. On September 10, 2014, the U.S. Court of Appeals for the Federal Circuit affirmed the US Patent and Trademark Office's Patent Trial and Appeal Board's decision to reject all claims of the Patents. On June 1, 2015, the U.S. Supreme Court denied SPP's petition to review the Federal Circuit's decision. SPP has now exhausted all possibilities to seek review or reconsideration of the USPTO's rejections. It is expected that the USPTO will issue reexamination certificates canceling all claims of the Patents and the district court will dismiss all claims of alleged infringement of the Patents with prejudice. Biotage has also filed requests for reexamination of all patent claims in the US patent no 8,066,875 B2, which is a continuation of US patent no 7,381,327, and US patent no 8,070,957, which is a continuation of the US patent 7,410,571. All claims of the `875 and `957 patent are rejected, and SPP has appealed to the USPTO Patent Trial and Appeal Board. SPP asserted these patents in district court in a separate lawsuit, which is also stayed pending reexamination.

Biotage AB Approves Dividend

The board of directors of Biotage AB announced annual general meeting to be held on April 28, 2015, approved a dividend of SEK 0.75 per share, which in aggregate is a dividend in the amount of no higher than SEK 48,535, 835 and to carry forward SEK 428,680,080. Record date for dividend was resolved to be 30 April 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOT:SS kr18.00 SEK +0.40

BIOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $11.70 USD +0.32
International Stem Cell Corp $3.98 USD +0.33
Luminex Corp $18.46 USD -0.07
QIAGEN NV €23.70 EUR +0.34
Sequenom Inc $2.23 USD +0.09
View Industry Companies
 

Industry Analysis

BIOT

Industry Average

Valuation BIOT Industry Range
Price/Earnings 18.4x
Price/Sales 2.1x
Price/Book 2.3x
Price/Cash Flow 18.4x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTAGE AB, please visit www.biotage.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.